From 13thto 16thof September, to important meetings took place in Vienna: the EHA Business Meeting and the EHDN Plenary Meeting. [...]
The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that […]
Read about the Registery journey from the very beginning to the more recent successor study Enroll-HD. Cristina Ferreira gives you […]
Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership […]
Yesterday Ionis Pharmaceutical presented new data from their Huntingtin lowering trial, IONIS-HTTRx. The data demonstrates a relationship between reduction of […]
The biotechnology company Wave Life Sciences strengthens their efforts in Huntington’s disease. In February they announced their collaboration with Takeda, […]
News and updates from the latest CHDI Therapeutics conferences have now been subtitled! In the video you can learn more [...]
Today Ionis and Roche have announced more details from the Huntingtin lowering trial. The initial results was released in December […]
When the groundbreaking results of the Huntingtin lowering trial, IONIS-HTTRx, was announced the European Huntington Association travelled to Basel to […]
This December IONIS Pharmaceuticals announced their groundbreaking results from the first Huntingtin lowering trial in humans (called IONIS-HTTRx). At the […]
Funding Partner
Follow us